RevBio Inc. news
RevBio, Inc., announced that it has been awarded a Phase II Small Business Innovation Research (SBIR) grant expected to total $2 million over two years from the National Institute on Aging, part of the National Institutes of Health. This funding will allow the company to pursue the treatment of wrist fractures with its patented bone adhesive technology known as Tetranite®. Because the bo
LaunchPad Medical, Inc. announced that it has received approval from the Medicines and Healthcare products Regulatory Agency in the United Kingdom to start a 15-patient pilot clinical study to examine the safety and efficacy of Tetranite, the company`s bone adhesive biomaterial, to immediately stabilize dental implants following tooth extractions.
This study will focus specifically on anterior teeth located in
Executives from LaunchPad Medical, Inc. announced that the company has rebranded. Its new name, RevBio, was chosen since it more accurately portrays the objective of developing its revolutionary Tetranite® bone adhesive biomaterial platform. The company has also adapted a tag line "Transforming Bone Repair" which better defines the company`s musculoskeletal focus in developing products for both dental and orthopedic applications where its patented biomaterial could signi
LaunchPad Medical, Inc. announced that it has received follow-on support of up to $1.8 million from the Michigan-Pittsburgh-Wyss Regenerative Medicine Resource Center which w
RevBio, Inc., announced that it has been awarded the opportunity to conduct an in vivo research experiment on the International Space Station U.S. National Laboratory (ISS National Lab). This experiment will examine the biomaterial`s osteoconductivity when used in a microgravity environment where bone density and the ability to regenerate new bone tissue is significantly compromised.
"Given the competitive nature of this a